US-based medical technology company Inspira has unveiled an advanced capability to simulate both the arterial and venous blood parameters of patients with specific medical conditions.

Developed by the company’s in-house team, the platform eliminates the need for in vivo animal testing and simulates human blood conditions based on predefined medical profiles.

The platform has played a key role in the development of the HYLA Blood Sensor and VORTX Orbiting blood oxygenation delivery systems, which are the core of the Inspira ART500.

Its unique settings will facilitate the continuous and real-time management of blood parameters for a range of blood flow rates.

It imitates a patient’s oxygen-deficient and carbon dioxide-rich blood after it has flowed through body organs and tissues, said the US medical device maker.

Inspira Technologies chief technology officer Daniella Yeheskely-Hayon said: “Inspira Technologies focuses on developing advanced blood monitoring and oxygen delivery technologies through its high-end testing platforms which allows it to perform wider range-controlled testing while minimizing the need to perform in vivo animal testing.”

Inspira said that the advanced capabilities may enable further expansion of its research within a shorter timeframe and with a better use of resources, thereby reducing time and costs.

The enhanced access to data contributes to advancement in the development, testing and release of new technologies and products along with verification and validation before regulatory submissions.

The bio-mimicking platform allows Inspira to control a broad range of blood parameters.

Also, it will allow the testing of the company’s technologies in critical scenarios, such as simulating the blood parameters of patients who may suffer from acute medical conditions.

The company’s high-end lab capabilities include the monitoring of oxygen and carbon dioxide levels and detecting hemolysis and other key parameters under extreme conditions.

Inspira is a medical technology company focused on respiratory diseases and has developed an augmented respiration technology (INSPIRA ART), to rebalance oxygen saturation levels.

INSPIRA ART allows the patients to remain awake during the treatment while reducing the need for highly invasive, risky, and mechanical ventilation systems needing medically induced coma.